AI-Designed Drug Candidate Moves Closer to Parkinson’s Clinical Trials

Insilico Medicine has completed key preclinical studies for ISM8969, a potential new oral treatment for Parkinson’s disease that targets brain inflammation — a process thought to contribute to disease progression. Developed with Artificial Intelligence Using its Pharma.AI platform, Insilico created ISM8969 to cross the blood-brain barrier and directly address inflammation. In animal models, the drug improved movement and motor skills in a dose-dependent way, with some results approaching the performance of healthy animals. Why This Matters Current Parkinson’s treatments mostly manage symptoms. ISM8969 targets NLRP3, a protein linked to chronic inflammation, with the goal of slowing or changing the course of the disease. Next Steps Insilico plans to apply for regulatory approval in late 2025 to begin human clinical trials — marking the first step in testing whether this inflammation-targeting strategy could work for people with Parkinson’s. Looking Ahead If successful, ISM8969 could represent a shift toward treatments that address the root causes of Parkinson’s, potentially offering more effective and longer-lasting benefits.